S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55

Lucira Health Stock Forecast, Price & News

-0.45 (-7.00%)
(As of 01/18/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
186,738 shs
Average Volume
233,582 shs
Market Capitalization
$234.57 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive LHDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Lucira Health and its competitors with MarketBeat's FREE daily newsletter.

Lucira Health logo

About Lucira Health

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.


See More Headlines

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$270 thousand


Net Income
$-37.35 million
Net Margins
Pretax Margin




Free Float
Market Cap
$234.57 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.55 out of 5 stars

Medical Sector

1063rd out of 1,414 stocks

Diagnostic Substances Industry

13th out of 25 stocks

Analyst Opinion: 2.8Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Lucira Health (NASDAQ:LHDX) Frequently Asked Questions

Is Lucira Health a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucira Health in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Lucira Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LHDX, but not buy additional shares or sell existing shares.
View analyst ratings for Lucira Health
or view top-rated stocks.

Are investors shorting Lucira Health?

Lucira Health saw a decline in short interest in December. As of December 31st, there was short interest totaling 473,000 shares, a decline of 44.9% from the December 15th total of 858,700 shares. Based on an average trading volume of 279,300 shares, the days-to-cover ratio is presently 1.7 days. Approximately 1.7% of the company's stock are sold short.
View Lucira Health's Short Interest

When is Lucira Health's next earnings date?

Lucira Health is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022.
View our earnings forecast for Lucira Health

How were Lucira Health's earnings last quarter?

Lucira Health, Inc. (NASDAQ:LHDX) released its earnings results on Thursday, November, 11th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.04. The firm had revenue of $14.98 million for the quarter, compared to analyst estimates of $18 million. Lucira Health had a negative trailing twelve-month return on equity of 43.84% and a negative net margin of 230.43%.
View Lucira Health's earnings history

What guidance has Lucira Health issued on next quarter's earnings?

Lucira Health updated its fourth quarter 2021 earnings guidance on Thursday, December, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $30 M-, compared to the consensus revenue estimate of $28.40 million.

What price target have analysts set for LHDX?

3 Wall Street analysts have issued 12-month price targets for Lucira Health's stock. Their forecasts range from $9.00 to $9.00. On average, they anticipate Lucira Health's share price to reach $9.00 in the next year. This suggests a possible upside of 50.5% from the stock's current price.
View analysts' price targets for Lucira Health
or view top-rated stocks among Wall Street analysts.

Who are Lucira Health's key executives?

Lucira Health's management team includes the following people:
  • Mr. Erik T. Engelson, Pres, CEO & Director (Age 61, Pay $369.69k)
  • Dr. Debkishore Mitra Ph.D., CTO & Director (Age 34, Pay $311.35k)
  • Ms. Kelly Lewis Brezoczky, Exec. VP of Commercialization, Regulatory, Clinical & Bus. Devel. (Age 57, Pay $360.21k)
  • Mr. Daniel V. George, CFO & Treasurer (Age 51)
  • Mr. Hansgregory Charles Hartmann, Chief Operating Officer (Age 63)
  • Greg Chodaczek, Investor Relations
  • Mr. Kevin Walter Collins, Chief Revenue Officer
  • Ms. Tamanna Prashar, VP of Global Supply Chain, Operations & Quality (Age 40)

When did Lucira Health IPO?

(LHDX) raised $125 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. BofA Securities, William Blair and LifeSci Capital acted as the underwriters for the IPO.

What is Lucira Health's stock symbol?

Lucira Health trades on the NASDAQ under the ticker symbol "LHDX."

Who are Lucira Health's major shareholders?

Lucira Health's stock is owned by a number of institutional and retail investors. Top institutional investors include Cutler Group LP (0.00%).
View institutional ownership trends for Lucira Health

Which major investors are selling Lucira Health stock?

LHDX stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Lucira Health
or view top insider-selling stocks.

How do I buy shares of Lucira Health?

Shares of LHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lucira Health's stock price today?

One share of LHDX stock can currently be purchased for approximately $5.98.

How much money does Lucira Health make?

Lucira Health has a market capitalization of $234.57 million and generates $270 thousand in revenue each year.

How many employees does Lucira Health have?

Lucira Health employs 57 workers across the globe.

What is Lucira Health's official website?

The official website for Lucira Health is www.lucirahealth.com.

Where are Lucira Health's headquarters?

Lucira Health is headquartered at 1412 62ND STREET, EMERYVILLE CA, 94608.

How can I contact Lucira Health?

Lucira Health's mailing address is 1412 62ND STREET, EMERYVILLE CA, 94608. The company can be reached via phone at 510-350-8071.

This page was last updated on 1/19/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact[email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.